Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07205796) titled 'A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants' on Sept. 26.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd
Condition:
Herpes Zoster
Intervention:
Biological: HZ Vaccine (IN001)
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: May 1, 2026
Target Sample Size: 48...